

# Djawid Hashemi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9064315/publications.pdf>

Version: 2024-02-01

14  
papers

189  
citations

1163117

8  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

301  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the <scp>MOLITOR</scp> study. ESC Heart Failure, 2018, 5, 288-296.	3.1	26
2	CMR Tissue Characterization in Patients with HFmrEF. Journal of Clinical Medicine, 2019, 8, 1877.	2.4	26
3	The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. ESC Heart Failure, 2021, 8, 829-841.	3.1	24
4	Range Variability in CMR Feature Tracking Multilayer Strain across Different Stages of Heart Failure. Scientific Reports, 2019, 9, 16478.	3.3	20
5	Heart failure awareness survey in Germany: general knowledge on heart failure remains poor. ESC Heart Failure, 2017, 4, 224-231.	3.1	18
6	Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction. ESC Heart Failure, 2020, 7, 3240-3245.	3.1	17
7	Reliability of peripheral arterial tonometry in patients with heart failure, diabetic nephropathy and arterial hypertension. Vascular Medicine, 2017, 22, 292-300.	1.5	16
8	Variability of Myocardial Strain During Isometric Exercise in Subjects With and Without Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 111.	2.4	13
9	Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging. ESC Heart Failure, 2021, 8, 890-897.	3.1	10
10	Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trial. ESC Heart Failure, 2020, 7, 786-793.	3.1	6
11	Influence of baseline parameters on one-year physical, mental, and health-related quality of life in patients with heart failure and preserved ejection fraction. ESC Heart Failure, 2021, , .	3.1	5
12	Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. ESC Heart Failure, 2020, 7, 942-952.	3.1	4
13	Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial. Cells, 2021, 10, 2796.	4.1	3
14	Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial. European Journal of Heart Failure, 2020, 22, 559-561.	7.1	0